CANBERRA HEALTH SERVICES

Australian Researchers Launch World-First Clinical Trial of PMR-116 to Target 'Undruggable' MYC-Driven Cancers

- A world-first clinical trial targeting MYC-driven cancers will begin later this year, led by researchers from The Australian National University and funded by the Medical Research Future Fund. - The experimental drug PMR-116 targets approximately 70% of all cancers by inhibiting a pathway downstream of the MYC protein, which has long been considered 'undruggable' due to its disordered structure. - The basket trial design will include patients with multiple cancer types including prostate, breast, ovarian, and haematological cancers, all unified by MYC protein involvement rather than cancer type. - Clinical trials will be conducted across major Australian cancer centers including Canberra Hospital, Peter MacCallum Cancer Centre, and St Vincent's Hospital Sydney.